Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States
The aim of this study was to systematically evaluate state Medicaid policies for the treatment
of hepatitis C virus (HCV) infection with sofosbuvir in the United States. Medicaid …
of hepatitis C virus (HCV) infection with sofosbuvir in the United States. Medicaid …
Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis
Background. Although guidelines recommend that people who inject drugs (PWID) should
not be excluded from hepatitis C (HCV) treatment, some services remain reluctant to treat …
not be excluded from hepatitis C (HCV) treatment, some services remain reluctant to treat …
[HTML][HTML] EASL Clinical Practice Guidelines: management of hepatitis C virus infection
European Association For The Study Of The Liver - Journal of hepatology, 2014 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide. The long-term impact of HCV infection is highly variable, from minimal changes …
worldwide. The long-term impact of HCV infection is highly variable, from minimal changes …
Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection
Since 2000 outbreaks of acute hepatitis C virus (HCV) among HIV-positive men who have
sex with men (MSM) who denied injecting drug use have been reported from Europe, the …
sex with men (MSM) who denied injecting drug use have been reported from Europe, the …
Recommendations for the management of hepatitis C virus infection among people who inject drugs
In high income countries, the majority of new and existing hepatitis C virus (HCV) infections
occur among people who inject drugs (PWID). In many low and middle income countries …
occur among people who inject drugs (PWID). In many low and middle income countries …
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine
Hepatitis C virus (HCV) was discovered more than two decades ago, but progress towards a
vaccine has been slow. HCV infection will spontaneously clear in about 25% of people …
vaccine has been slow. HCV infection will spontaneously clear in about 25% of people …
Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility
NK Martin, P Vickerman, GR Foster, SJ Hutchinson… - Journal of …, 2011 - Elsevier
BACKGROUND & AIMS: Hepatitis C virus antiviral treatment is effective for individual
patients but few active injecting drug users are treated. We considered the utility of antiviral …
patients but few active injecting drug users are treated. We considered the utility of antiviral …
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection
Background & Aims Shortened duration therapy for acute and recent HCV infection has
been shown to be highly effective in several small non-randomised studies with direct-acting …
been shown to be highly effective in several small non-randomised studies with direct-acting …
[PDF][PDF] The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs
With the development of new highly efficacious direct‐acting antiviral (DAA) treatments for
hepatitis C virus (HCV), the concept of treatment as prevention is gaining credence. To date …
hepatitis C virus (HCV), the concept of treatment as prevention is gaining credence. To date …
Management of acute HCV infection in the era of direct-acting antiviral therapy
The management of acute HCV infection has not been standardized following the
availability of direct-acting antiviral agents (DAAs) for chronic HCV infection, and substantial …
availability of direct-acting antiviral agents (DAAs) for chronic HCV infection, and substantial …